Locoregional Treatment of IDC Flashcards
NSABP B17
RCT: BCS vs BCS + RT for localised DCIS
Conclusion: addition of RT after BCS significantly reduces ipsilateral breast cancer recurrence
NSABP B24
Tamoxifen after BCS + RT in DCIS patients
Conclusion: reduced incidence of invasive breast cancer
Evidence for BCT + RT treatment in IDC
NSABP B17
EORTC 10853
ECOG E5194
Indications for Mastectomy in IDC
- >4cm
- Multicentric disease
- Local recurrence following BCS
- Contraindications / do not want RT
- Male
- Inflammatory carcinoma
Contraindications to radiotherapy
- Absolute
- Pregnancy
- Previous RT
- Relative
- Active connective tissue disease
- Known BRCA
Radiotherapy regimen in BCS + RT
- 50 Gy to whole breast
- 10Gy boost over operative site
- daily for 5-6 weeks
- 2-3 weeks after surgery
Types of positive SLNB and associated management
- Isolated Tumor cells → no need ALND
- Micrometastasis → no need ALND
- Macrometastasis
- ≤2 → no further dissection if T2 or less
- 3 or more → ALND
Definition of isolated tumor cells
≤ 0.2mm tumor cells
Definition of micrometastasis
0.2-2mm tumor cells
Definition of macrometastasis
>2mm tumor cells in SLNB
Why use dual tracer technique for SLNB?
- increased accuracy
- Radioactive colloid → accuracy 90%
- blue dye → accuracy 80%
- dual agent → accuracy 97-98%
Evidence of SLNB for axillary management in clinically node negative
ALMANAC
- level 1 evidence
- improved quality of life outcomes
- improved arm morbidity
- no difference in overall survival
What is Z0011 eligibiltiy criteria
- Refers to subset of patient with early stage IDC that may not require further axillary surgery
- Criteria:
- T1/T2
- Clinically node negative
- Less than 3 metastatic SLN
- Will undergo BCS + RT
What is the Z0011 trial
- multicenter non-inferiority RCT
- Patients: T1/T2 clinical node negative
- Intervention: (BCT + RT) +ALND vs SLNB only
- Outcome: 10 year survival
- Conclusion: ALND not necessary for 1-2 nodes
- Criticism: low accrural, premature study termination
Evidence for axillary management in early IDC cancer
Z0011
AMAROS
IBCSG 23-01
POSNAC (pending)
ALLIANCE
SOUND
Indications for ALND
- 3 more metastatic sentinel LN
- 1-2 SLN metastastsis in patients who do not want or cannot have whole breast irradiation
Indication for adjuvant radiotherapy
- skin and chest wall involvement
- Inflammatory cancers
- >4 axillary LN met
Principle of Breast Conservative Surgery
- WLE + RT
- Titanium clips should be attached to pectoral muscle at base fo tumorectomy site
- Specimen shoudl be oriented by suture/ clips
- Eclipse of skin should be excised if attached to skin
- No ink tumor margin
Definition of Modified Radical Masectomy
Removal of
- all breast tissue (total mastectomy)
- ALND Level I + II
- preservation of pectoralis major + minor and overlying skin
Describe the MRM procedure
- Supine with ipsilateral arm secure to arm board
- Transverse elliptical incision encompassing NAC and lump
-
Elevate superior and inferior skin flaps in plane between subcutaneous and breast tissue
- superior: until lower border of clavicle
- inferior: superior border of rectus sheath
- medial: periphery of the breast disc
- lateral: latissimus dorsi
- Dissect down to chest wall to pectoralis fascia then along fascia from medial to lateral to lift breast tissue enbloc from the chest wall
- Identify the border of pectoralis major and clear axillary tail
- Wash cavity with water to eliminate any solitary tumor cells & unvascularize fat globules
Boundaries of dissection for ALND
- Superior: axillary vein
- Inferior: upper lateral breast tissue/axillary fascia
- Medial: lateral border of pectoralis major + clear LN posterior to pect minor
- Lateral: anterior of LD
- Anterior: clavicopectoral fascia
- Posterior subscapularis
Intra-operative methods for SLN assessment
- Frozen section
- Touch imprint cytology
- Molecular technique (OSNA- one step nucleic acid amplification)
LocoPros and cons of intraoperative assessment techniques
- Frozen section:
- +tissue retained for future reference, + sensitive (55-75%) and specific
- -requires on hand pathologist, -
- Touch imprint cytology
- high specificity, +retained tissued for future reference
- -pathologist on hand, - low sensitivity
- OSNA
- +high specificity and sensitivity, + able to quantify between macro/micro/ITC
- -expensive equipment, -no tissue left for furthre assessment
When would you perform Level 3 axillary clearance?
Only in melanoma